In vivo evaluation of the acute thrombogenicity of the modified human umbilical vein and autologous artery.
With the aim to evaluate acute thrombogenicity, segments of human umbilical vein grafts (Dardik Biograft, Meadox Medicals, Inc., Oakland, N.J.), nonheparinized, heparin-alcohol-treated, or covalently heparinized, were implanted into the carotid arteries of sheep. Autologous carotid arteries were used as control grafts. Flow was restricted to 25 ml/min. Accumulation of autologous 32P-labeled platelets was registered at both anastomotic and midgraft regions for 240 minutes. At the end of the perfusion period, grafts were removed, opened longitudinally, and the thrombus-free surface (TFS) and thrombus weight determined. The ex vivo determinations showed good correlation with results obtained with in vivo registration. In vivo accumulation of platelets was significantly larger in nonheparinized human umbilical vein grafts compared with heparin-alcohol treated grafts. Covalently heparinized grafts showed a tendency toward lower radioactive values, but visual examination after perfusion revealed areas of "intimal" damage with thrombotic deposits, probably caused by heparinization procedure. Autologous arteries showed the largest TFS and the smallest thrombi. Platelet accumulation in autologous arteries decreased almost to reference values after an initial rapid increase. In conclusion, heparin-alcohol treatment of human umbilical vein grafts reduces acute thrombogenicity. Although covalent heparin bonding seems to act in the same way, the fragility of the graft appears to preclude use of this method. Autologous arteries exhibit excellent antithrombotic characteristics.
D000208:Acute Disease; D000818:Animals; D001792:Blood Platelets / Q000473:pathology; D001807:Blood Vessel Prosthesis / Q000009:adverse effects*; D004195:Disease Models, Animal; D005263:Femoral Artery / Q000473:pathology / Q000637:transplantation*; D006083:Graft Occlusion, Vascular / Q000097:blood / Q000209:etiology / Q000473:pathology; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D012756:Sheep; D013927:Thrombosis / Q000150:complications / Q000209:etiology* / Q000473:pathology; D013997:Time Factors; D014471:Umbilical Veins / Q000473:pathology / Q000637:transplantation*
D006493:Heparin